Cargando…

794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy

BACKGROUND: Pulmonary tuberculosis (TB) remains one of the leading infectious causes of morbidity and mortality worldwide. Most data showed that infectiousness of pulmonary TB diminishes rapidly after 2 weeks of effective anti-tuberculous therapy and the bacilli seen in the smear after 2 weeks are m...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhowady, Faraj, Elmaki, Nada, Ali, Maisa, Husain, Ahmad, Al-Maslamani, Muna, Alsuwaidi, Zubaida, Mohamed, Mahmoud, Alsoub, Hussam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254249/
http://dx.doi.org/10.1093/ofid/ofy210.801
_version_ 1783373681471258624
author Alhowady, Faraj
Elmaki, Nada
Ali, Maisa
Husain, Ahmad
Al-Maslamani, Muna
Alsuwaidi, Zubaida
Mohamed, Mahmoud
Alsoub, Hussam
author_facet Alhowady, Faraj
Elmaki, Nada
Ali, Maisa
Husain, Ahmad
Al-Maslamani, Muna
Alsuwaidi, Zubaida
Mohamed, Mahmoud
Alsoub, Hussam
author_sort Alhowady, Faraj
collection PubMed
description BACKGROUND: Pulmonary tuberculosis (TB) remains one of the leading infectious causes of morbidity and mortality worldwide. Most data showed that infectiousness of pulmonary TB diminishes rapidly after 2 weeks of effective anti-tuberculous therapy and the bacilli seen in the smear after 2 weeks are most likely nonviable. We aim to assess this hypothesis by doing sputum culture after 2 weeks of therapy to assess the viability of the bacilli in the smear. METHODS: A prospective cohort study was conducted on patients admitted to Communicable Disease Centre (CDC), Qatar with smear positive pulmonary tuberculosis during the period November 2013–November 2014. We repeated sputum smear and culture after 2 weeks of rifampicin based regimen to assess the infectivity. Demographic and clinical characteristics of patients was evaluated and compared with smear and culture conversion rate. RESULTS: Ninety-five cases were included in the study. All had sputum smear and culture after 2 weeks of supervised rifampicin based therapy (Table 1). Sputum culture at two weeks of treatment was positive in 91 cases (95.7%) and only four cases were culture negative after 2 weeks. Demographic and clinical characteristics were compared with the culture status after 2 weeks, found Patient from Indian subcontinent and symptoms duration more than 1 month are less likely to clear infection after 2 weeks with P-value 0.01 and 0.009, respectively (Table 2). [Image: see text] [Image: see text] The calculated mean for sputum smear and culture conversion rate was 4 and 8 weeks, respectively. The presence of cough and the duration of symptoms were associated significantly with rapid sputum conversion (P < 0.05); however, the presence of cavity on CXR had no statistical significant effect (Table 3). [Image: see text] CONCLUSION: Majority of our patients in the study have positive TB culture after two weeks of rifampicin based anti-tuberculosis therapy. So, discontinuation of the isolation after 2 weeks of treatment assuming that bacilli in the smear are nonviable may not be safe. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254249
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62542492018-11-28 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy Alhowady, Faraj Elmaki, Nada Ali, Maisa Husain, Ahmad Al-Maslamani, Muna Alsuwaidi, Zubaida Mohamed, Mahmoud Alsoub, Hussam Open Forum Infect Dis Abstracts BACKGROUND: Pulmonary tuberculosis (TB) remains one of the leading infectious causes of morbidity and mortality worldwide. Most data showed that infectiousness of pulmonary TB diminishes rapidly after 2 weeks of effective anti-tuberculous therapy and the bacilli seen in the smear after 2 weeks are most likely nonviable. We aim to assess this hypothesis by doing sputum culture after 2 weeks of therapy to assess the viability of the bacilli in the smear. METHODS: A prospective cohort study was conducted on patients admitted to Communicable Disease Centre (CDC), Qatar with smear positive pulmonary tuberculosis during the period November 2013–November 2014. We repeated sputum smear and culture after 2 weeks of rifampicin based regimen to assess the infectivity. Demographic and clinical characteristics of patients was evaluated and compared with smear and culture conversion rate. RESULTS: Ninety-five cases were included in the study. All had sputum smear and culture after 2 weeks of supervised rifampicin based therapy (Table 1). Sputum culture at two weeks of treatment was positive in 91 cases (95.7%) and only four cases were culture negative after 2 weeks. Demographic and clinical characteristics were compared with the culture status after 2 weeks, found Patient from Indian subcontinent and symptoms duration more than 1 month are less likely to clear infection after 2 weeks with P-value 0.01 and 0.009, respectively (Table 2). [Image: see text] [Image: see text] The calculated mean for sputum smear and culture conversion rate was 4 and 8 weeks, respectively. The presence of cough and the duration of symptoms were associated significantly with rapid sputum conversion (P < 0.05); however, the presence of cavity on CXR had no statistical significant effect (Table 3). [Image: see text] CONCLUSION: Majority of our patients in the study have positive TB culture after two weeks of rifampicin based anti-tuberculosis therapy. So, discontinuation of the isolation after 2 weeks of treatment assuming that bacilli in the smear are nonviable may not be safe. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254249/ http://dx.doi.org/10.1093/ofid/ofy210.801 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Alhowady, Faraj
Elmaki, Nada
Ali, Maisa
Husain, Ahmad
Al-Maslamani, Muna
Alsuwaidi, Zubaida
Mohamed, Mahmoud
Alsoub, Hussam
794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy
title 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy
title_full 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy
title_fullStr 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy
title_full_unstemmed 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy
title_short 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy
title_sort 794. infectivity of smear-positive pulmonary tb after 2 weeks of rifampicin-based anti-tuberculous therapy
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254249/
http://dx.doi.org/10.1093/ofid/ofy210.801
work_keys_str_mv AT alhowadyfaraj 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT elmakinada 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT alimaisa 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT husainahmad 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT almaslamanimuna 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT alsuwaidizubaida 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT mohamedmahmoud 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy
AT alsoubhussam 794infectivityofsmearpositivepulmonarytbafter2weeksofrifampicinbasedantituberculoustherapy